Mecasermin (rh-IGF-1) treatment for Rett Syndrome is safe and well-tolerated

(International Rett Syndrome Foundation) The results from Boston Children's Hospital's Phase 1 human clinical trial in Rett syndrome came out today. A team of investigators successfully completed a Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)], showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.

Source: EurekAlert! - Biology - March 10, 2014 Category: Biology Source Type: news